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Specific cyclic ADP-ribose 
phosphohydrolase obtained by 
mutagenic engineering of Mn2+-
dependent ADP-ribose/CDP-alcohol 
diphosphatase
João Meireles Ribeiro1, José Canales1, Alicia Cabezas1, Joaquim Rui Rodrigues  2, Rosa María 
Pinto1, Iralis López-Villamizar1,3, María Jesús Costas1 & José Carlos Cameselle  1
Cyclic ADP-ribose (cADPR) is a messenger for Ca2+ mobilization. Its turnover is believed to occur by 
glycohydrolysis to ADP-ribose. However, ADP-ribose/CDP-alcohol diphosphatase (ADPRibase-Mn) 
acts as cADPR phosphohydrolase with much lower efficiency than on its major substrates. Recently, 
we showed that mutagenesis of human ADPRibase-Mn at Phe37, Leu196 and Cys253 alters its specificity: 
the best substrate of the mutant F37A + L196F + C253A is cADPR by a short difference, Cys253 
mutation being essential for cADPR preference. Its proximity to the ‘northern’ ribose of cADPR in 
docking models indicates Cys253 is a steric constraint for cADPR positioning. Aiming to obtain a specific 
cADPR phosphohydrolase, new mutations were tested at Asp250, Val252, Cys253 and Thr279, all near the 
‘northern’ ribose. First, the mutant F37A + L196F + C253G, with a smaller residue 253 (Ala > Gly), 
showed increased cADPR specificity. Then, the mutant F37A + L196F + V252A + C253G, with another 
residue made smaller (Val > Ala), displayed the desired specificity, with cADPR kcat/KM ≈20–200-fold 
larger than for any other substrate. When tested in nucleotide mixtures, cADPR was exhausted while 
others remained unaltered. We suggest that the specific cADPR phosphohydrolase, by cell or organism 
transgenesis, or the designed mutations, by genome editing, provide opportunities to study the effect 
of cADPR depletion on the many systems where it intervenes.
Cyclic ADP-ribose (cADPR) is a messenger that increases cytosolic calcium mainly by ryanodine receptor-mediated 
release from endoplasmic reticulum and also by extracellular influx through the opening of TRPM2 channels1–4. 
Given the wide variety of cell processes affected by calcium, many physiological and pathological situations can 
be mediated by cADPR in different systems, including animals, plants and protozoa. In mammals, it is an impor-
tant player in processes such as: inflammatory and immune responses, including neutrophil chemotaxis5 and T 
cell activation6; smooth muscle cell contraction in arteries and bronchi, with participation in the hypoxic pul-
monary vasoconstriction7,8 and in the pathogenesis of inflammatory/allergic airway diseases9,10; myometrium 
contractility, eventually contributing to delivery11,12; myocyte contraction in adult cardiac tissue13, participat-
ing in angiotensin II- and β-adrenergic-induced cardiac hypertrophy14,15 and in isoproterenol-induced arrhyth-
mias16; endocrine and exocrine pancreatic secretion17,18, although its role in insulin secretion and diabetes is 
controversial19; cell proliferation and differentiation, regulating e.g. expansion of human mesenchymal stem cells 
and hemopoietic progenitors20,21, neuronal differentiation of PC12 cells22, and cardiomyocyte differentiation of 
mouse embryonic stem cells23; and social behaviour in mice, including memory formation and spatial learn-
ing24,25, related to oxytocin secretion26,27 and maybe to niacin deficiency28. Furthermore, cADPR is involved in egg 
activation and fertilization in ascidians29 and sea urchin30, in early development in sea urchin31, in abscisic acid 
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signalling in sponges32 and plants33,34, in cell fission in dinoflagellates35, and in Toxoplasma gondii pathogenic-
ity36–38. This large series of cADPR effects indicates that tools allowing the manipulation of cADPR concentration 
could be useful in different scenarios.
Concerning cADPR metabolism, in the mollusc Aplysia it is synthesized from NAD+ by a specific ADP-ribosyl 
cyclase39–41. However, in mammals cADPR is formed by a collateral reaction of NAD glycohydrolases CD38 and 
Bst-1/CD157 alternative to the direct formation of ADP-ribose. These mammalian proteins catalyse also cADPR 
turnover to ADP-ribose, by hydrolysis of the N1-glycosidic bond42–49.
The phosphoanhydride linkage of cADPR is not attacked by broad-specificity phosphohydrolases43,50,51, 
like snake venom phosphodiesterase, active towards many phosphodiester and phosphoanhydride derivatives 
of 5′-nucleotides, among them ADP-ribose52–54. Therefore, it is noteworthy that mammalian Mn2+-dependent 
ADP-ribose/CDP-alcohol diphosphatases (ADPRibase-Mn; EC 3.6.1.53) hydrolyse the phosphoanhydride link-
age of cADPR to N1-(5-phosphoribosyl)-AMP (pRibAMP) (Fig. 1) with a low but considerable catalytic efficiency 
(≈150-fold lesser than that of ADP-ribose hydrolysis)51,55. This minor activity could be part of a route for the 
turnover of cADPR, as both this compound and the ADPRibase-Mn product, pRibAMP, have been detected in 
human red blood cells infected with Plasmodium falciparum56. The possible physiological role of the enzymatic 
phosphohydrolysis of cADPR by ADPRibase-Mn is uncertain because the magnitude of the activity is small 
compared to its major activities. The enzyme has been studied in mammals (Rattus norvegicus and Homo sapi-
ens)51,55,57,58 and in the zebrafish (Danio rerio)59. It is named after their best substrates (numbers in parenthesis 
are kcat/KM values, i.e. the specificity constants or catalytic efficiencies): ADP-ribose (3.3–5.9 × 105 M−1 s−1) and 
CDP-alcohols (0.1–1.5 × 105 M−1 s−1), but it hydrolyses also e.g. 2′,3′-cAMP and ADP. In addition, the mamma-
lian ADPRibase-Mn, but not the zebrafish enzyme, hydrolyse cADPR. ADPRibase-Mn specificity is underscored 
by the lack of activity on ADP-glucose, UDP-glucose, CDP-glucose, CDP, CMP, AMP and 3′,5′-cAMP. Although 
the efficiency of cADPR phosphohydrolysis by mammalian ADPRibase-Mn (4.0 × 103 M−1 s−1) is low compared 
to the phosphohydrolysis of ADP-ribose, it has been earlier pointed out that the ratio between both activities is 
similar to the ratio of NAD glycohydrolase (i.e. ADP-ribose synthesis) to cADPR synthase activities of CD38 and 
Bst-1/CD15751.
ADPRibase-Mn enzymes (Fig. 2) contain the dinuclear metal centre typical of the metallo-dependent phos-
phatases SCOP2 superfamily60, forming within it a family of their own named as ADPRibase-Mn-like (ID 
4002589). ADPRibase-Mn proteins constitute also a functional family in the CATH classification, within cluster 
SC:3 of superfamily 3.60.21.1061. The dinuclear centre of ADPRibase-Mn contains a metal-bridging water which, 
either as such or as hydroxide, it is assumed to be activated by the metals and to attack one of the substrate phos-
phorus atoms. According to this model, important mechanistic aspects are the correct positioning of the substrate 
in the active centre for an in-line attack, and transition state stabilization by charge neutralization.
The molecular bases of catalysis and ADP-ribose preference of human ADPRibase-Mn have been investigated 
by structure-driven mutagenesis based upon substrate docking to a human protein model (Fig. 2)55. Two amino 
acids involved in catalysis have been identified: Arg43 and His111. The former probably stabilizes the transition 
state and/or the leaving group, due to the proximity of its positive side chain to the negative phosphoryl group(s) 
Figure 1. Phosphohydrolysis of cADPR. This is the reaction catalysed by a minor activity of mammalian 
ADPRibase-Mn51,55 and the very major activity of the artificial cADPR phosphohydrolase developed in this 
study by mutagenic engineering. The left-hand side ribose residue corresponds to the so-called ‘northern’ 
ribose. MarvinSketch 17.10.0, 2017, ChemAxon (http://www.chemaxon.com) was used for drawing the 
chemical structures of the reactants.
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of the substrate. On the other hand, His111 seems to be hydrogen bonded to the oxygen of the scissile P-O bond, 
keeping the substrate in an optimal orientation for in-line attack by the metal-activated nucleophile. Two other 
residues have been identified as determinants of specificity: Phe37 and Cys253. The former locates in the rim of the 
active site entrance, far away from the catalytic core and dimetallic centre. The interaction of the aromatic ring 
with the nitrogen base of ADP-ribose (Fig. 2a) determines the preference for this substrate. Mutation of Phe37 
to Ala increases the KM for ADP-ribose, with little effect on kcat or on the KMs for other substrates, such that the 
best F37A-ADPRibase-Mn substrate is CDP-choline instead of ADP-ribose. Cys253 is located in the bottom of the 
substrate cavity, near the catalytic core and dimetallic centre but without interacting with the metals. In models of 
enzyme-substrate complexes, the thiol group is near the non-nucleosidic ribose of ADP-ribose or the ‘northern’ 
cADPR ribose. Substitution of Cys253 by Ala elicits favourable effects in kcat and KM for cADPR, thus increasing the 
specificity constant for this substrate. Interestingly, the combination of F37A and C253A mutations, with a minor 
contribution also by L196F, results in an ADPRibase-Mn mutant that acts preferentially as cADPR phosphohy-
drolase, although conserves very substantial activities on the other substrates55.
Figure 2. Models of human ADPRibase-Mn with docked substrates. The coordinates for the models were 
taken from previous work55 and the structures were drawn with VMD 1.9.3 (http://www.ks.uiuc.edu/Research/
vmd/)77 under MacOSX. (a,b) Full view of ADPRibase-Mn with docked ADP-ribose (a) or cADPR (b) 
showing in both cases the amino acid residues that were mutated in this work. (c) Stereogram with the detail 
of cADPR docked to ADPRibase-Mn showing: (i) the ligand (dark blue, adenine; green, ‘southern’ ribose; 
purple, pyrophosphate; orange, ‘northern’ ribose); (ii) the metals (yellow) of the dinuclear centre with a bridging 
molecule of water (red) which is assumed to act as nucleophile in the reactions; (iii) amino acid residues bound 
to the metals (black), of which Gln27 and Asp110 have been mutated in previous work; (iv) other amino acids 
mutated previously but not in the current work (Arg43, His111 and Phe210); (v) amino acids mutated in the 
current work (Phe37, Leu196, Asp250, Val252, Cys253 and Thr279).
www.nature.com/scientificreports/
4SCIEnTIFIC RepoRts |  (2018) 8:1036  | DOI:10.1038/s41598-017-18393-9
Taking into account the variety of effects mediated by cADPR in multiple biological systems, it was envis-
aged that an artificial enzyme with specific cADPR phosphohydrolase activity of high catalytic efficiency would 
be a tool of considerable biotechnological interest. In principle, the behaviour of the triple mutant F37A + L1
96F + C253A-ADPRibase-Mn55 proves the feasibility of altering the substrate specificity of ADPRibase-Mn in 
favour of its activity towards cADPR and against the other known substrates. Following this thread, additional 
mutagenic engineering of ADPRibase-Mn was implemented and its effects on substrate specificity and catalytic 
efficiency were studied, which led to the finding of a quadruple mutant with a very high specificity as cADPR 
phosphohydrolase.
Results
Design of new mutations at or near residue 253 of human ADPRibase-Mn, in the vicinity of the 
adenine N1-linked (‘northern’) ribose of cADPR. Our recent study of human ADPRibase-Mn55 indi-
cates that the specificity of the native enzyme is changed by three mutations (F37A + L196F + C253A) from a 
clear-cut preference for ADP-ribose, with minor activity on cADPR, towards a relative preference for cADPR. 
Mutations F37A and L196F diminish the catalytic efficiency with all substrates but less strongly so for cADPR. 
C253A increases strongly the catalytic efficiency for cADPR but only weakly so for other substrates. In terms of 
the cADPR/ADP-ribose ratio of efficiencies, this set of combined mutations elicits a 500-fold increase, from 0.007 
for native ADPRibase-Mn to 3.2 for the F37A + L196F + C253A mutant. However remarkable this change may 
be, the resulting preference for cADPR as substrate is not very strong (see below and Fig. 3). The key mutation 
that favors cADPR phosphohydrolase activity is the removal of the thiol group of Cys253 (i.e. C253A). Since in 
models of cADPR docked to ADPRibase-Mn (Fig. 2) that thiol group is near the northern ribose, the effect of 
the mutation could be due to the removal of a steric constraint that hinders the positioning of the relatively rigid 
macrocyclic structure of cADPR in an optimal orientation to undergo attack by the metal-activated nucleophile. 
Conceivably, this would not occur to the other substrates, which are structurally rather different to cADPR.
To support the role of Cys253 as a steric constraint for cADPR, we constructed the single C253V mutant of 
ADPRibase-Mn, in which cysteine was replaced by the bigger valine residue. This mutant performed worse than 
the wild-type enzyme as cADPR phosphohydrolase. It hydrolysed ADP-ribose, CDP-choline and 2′,3′-cAMP with 
higher kcat than the wild-type enzyme, while displaying a decreased kcat for cADPR (Supplementary Table S1).
Based on this reasoning, novel mutations were implemented in residues near the position where the northern 
ribose of cADPR docks in the active centre of native ADPRibase-Mn. This included mutating Asp250, Val252, Cys253 
and Thr279 (Fig. 2b,c). In every case, the initial mutations F37A and L196F were maintained. Of the remaining 
mutations, C253G was introduced first to construct the triple mutant F37A + L196F + C253G. This change, by 
putting a side chain smaller than that of alanine in residue 253, was speculatively expected to diminish further the 
steric constraint to the optimal positioning of cADPR. Since the F37A + L196F + C253G mutant displayed in fact 
higher efficiency for cADPR than the F37A + L196F + C253A one (see below and Fig. 3), the mutations in Asp250, 
Val252 and Thr279 were introduced over the F37A + L196F + C253G background. All the additional mutations 
Figure 3. Relative specificity constants or catalytic efficiencies of the constructed mutants of ADPRibase-Mn 
for cADPR versus other selected substrates. The bars represent the ratios of the kcat/KM values for cADPR versus 
the kcat/KM values for the other substrates indicated. The numbers above the bars are the absolute kcat/KM values 
for the hydrolysis of cADPR estimated as described in Supplementary Fig. S1. Data for the wild-type enzyme 
and for the triple mutant F37A + L196F + C253A were obtained in previous work55.
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(D250A, V252A, V252G, T279A) were designed to diminish the size of the affected side chains in search of a 
combination that, by removing additional steric constraints, enhanced the specificity of the cADPR phosphohy-
drolase activity. In summary, five new multiple mutants of ADPRibase-Mn were prepared and assayed (Fig. 3).
Enzymatic characterization of ADPRibase-Mn mutants: a quadruple mutant highly specific as 
cADPR phosphohydrolase. The five multiple mutants were expressed as recombinant proteins and their 
kcat/KM values were estimated. Figure 3 shows the ratio of the efficiency recorded with cADPR as the substrate ver-
sus the efficiency recorded with other representative substrates (ADP-ribose, CDP-choline and 2′,3′-cAMP). For 
comparison, the same ratios are also shown for the wild-type enzyme and for the triple F37A + L196F + C253A 
mutant55. For wild-type ADPRibase-Mn, the efficiency ratios are very unfavourable to cADPR, with val-
ues of 0.007, 0.027 and 0.16 when the kcat/KM for cADPR is divided by that for ADP-ribose, CDP-choline and 
2′,3′-cAMP, respectively. Note that a ratio <1 indicates that cADPR is worse substrate than the other compound. 
This specificity pattern is already turned upside down in the F37A + L196F + C253A mutant, as the same ratios 
amount to 3.2, 1.6 and 8.9, making cADPR the best substrate of that ADPRibase-Mn mutant though not by a very 
large difference55.
Concerning the results obtained with the novel mutants, one should first note that changing the methyl group 
of Ala253 to the smaller side chain of Gly253 afforded considerable increases of those efficiency ratios in favour of 
cADPR: 15.0, 12.0 and 23.7, respectively. These changes were accounted for by a slight 1.3-fold increase of the 
efficiency with cADPR and a 2–6-fold decrease of the efficiency with the other substrates (Table 1).
Taking the behaviour of the triple mutant F37A + L196F + C253G as the baseline, one should note the oppos-
ing effects of additional mutations in Asp250 and Val252. The quadruple mutant F37A + L196F + D250A + C253G 
showed a detrimental effect of the D250A substitution on the efficiency with all substrates (1.3–3.4-fold decrease), 
and more markedly so for cADPR, such that the substrate efficiency ratios were less favourable than for the triple 
mutant F37A + L196F + C253G. In contrast, the quadruple mutant F37A + L196F + V252A + C253G showed 
detrimental effects of the V252A substitution on the efficiency with ADP-ribose, CDP-choline and 2′,3′-cAMP 
(1.1–2.8-fold decrease) while it increased 2-fold the efficiency with cADPR. The remarkable result of this muta-
tion set was that F37A + L196F + V252A + C253G-ADPRibase-Mn displayed substrate efficiency ratios highly 
favourable to cADPR: 80, 26 and 68, respectively when compared with ADP-ribose, CDP-choline and 2′,3′-cAMP 
(Fig. 3).
Further mutations were tested but they did not improve these figures. In contrast to what was observed with 
alanine and glycine substitutions at Cys253, the substitution of Val252 by glycine (F37A + L196F + V252G + C253G 
mutant) did not provide further increase of the specificity for cADPR compared to the substitution of Val252 by 
alanine. Finally, an additional mutation was introduced at Thr279. The resulting quintuple mutant F37A + L196F 
+ V252A + C253G + T279A showed an increased efficiency ratio cADPR/CDP-choline relative to its progenitor 
F37A + L196F + V252A + C253G. However, it was at the cost of a loss of absolute catalytic efficiency on cADPR 
and of the efficiency ratios cADPR/ADP-ribose and cADPR/2′,3′-cAMP.
Mutations to 
ADPRibase-Mn
F37A + L196F + C253A F37A + L196F + C253G
F37A + L196F + V252A + C253G (“specific cADPR 
phosphohydrolase”)
Specificity constant Specificity constant Specificity constant
Ratio of specificity constants 
(cADPR/alternative substrate)
Substrate (M−1 s−1)
Fold 
change (M−1 s−1)
Fold 
change (M−1 s−1)
Fold 
change Ratio Fold change
cADPR 35500 ± 4300 ↑9 46500 ± 8400 ↑12 90000 ± 7400 ↑23 — —
ADP-ribose 11000 ± 1700 ↓50 3100 ± 350 ↓180 1120 ± 75 ↓490 80 ↑11270
CDP-choline 22000 ± 2600 ↓7 3870 ± 420 ↓40 3500 ± 170 ↓44 26 ↑1012
CDP-ethanolamine 5800 ± 700 ↓8 1450 ± 85 ↓31 1740 ± 180 ↓26 52 ↑598
CDP-glycerol 22000 ± 4000 ↓3 6170 ± 560 ↓10 3870 ± 80 ↓17 23 ↑391
2′,3′-cAMP 4000 ± 800 ↓6 1960 ± 80 ↓12 1330 ± 70 ↓18 68 ↑414
Ap2A Not assayed — 800 ± 65 ↓43 420 ± 35 ↓83 214 ↑1909
NAD+ Not assayed — 1100 ± 6 ↓18 630 ± 40 ↓31 143 ↑713
NADH Not assayed — 700 ± 25 ↓30 470 ± 60 ↓45 191 ↑1035
FAD Not assayed — 4600 ± 750 ↓120 1620 ± 180 ↓341 56 ↑7843
NADP+ Not assayed — Not assayed — <50 ↓>7 >1800 ↑>158
NAADP Not assayed — Not assayed — <50 ↓>3 >1800 ↑>67
ATP Not assayed — <200 — <200 — >450 —
ADP <200 — <200 — <200 — >450 —
Table 1. Substrate specificity of the quadruple ADPRibase-Mn mutant F37A + L196F + V252A + C253G 
supporting its denomination and use as specific cADPR phosphohydrolase. The specificity constants 
(or catalytic efficiencies, kcat/Km) are means ± S.D. of three experiments. Data for the triple mutants 
F37A + L196F + C253A55 and F37A + L196F + C253G (this work) are shown for comparison. Changes (↑, 
increase; ↓, decrease) of the absolute specificity constants or of the ratio of specificity constants of cADPR 
relative to alternative substrates, are expressed versus the values for the human wild-type ADPRibase-Mn either 
reported previously55 or obtained in this work when not available.
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Taking into account all these results, the quadruple mutant F37A + L196F + V252A + C253G was chosen 
for detailed characterization with a series of known substrates of ADPRibase-Mn55,57,58 (see the Supplementary 
Fig. S1) and other compounds of interest. The resulting specificity is described in Table 1 in terms of absolute 
and relative values of kcat/KM. The engineered enzyme hydrolysed cADPR 23–26-fold more efficiently than 
CDP-glycerol and CDP-choline, which ranked second and third to cADPR, respectively, with even higher pref-
erence with respect to the other substrates. NAADP (another calcium regulator formed also by the cADPR 
synthase and CD384,62), its precursor NADP+, ATP and ADP were tested as substrates with negative results. 
For comparison, Table 1 shows also data for the previously described mutant F37A + L196F + C253A55, 
and for F37A + L196F + C253G, which served as an intermediate step towards the highly specific cADPR 
phosphohydrolase.
Demonstration of cADPR phosphohydrolase specificity in complex substrate mixtures. To test 
the specific action on cADPR even in the presence of potentially competing substrates, the engineered enzyme 
was incubated with mixtures of nucleotides. Figure 4 shows the HPLC analysis of a mixture containing 0.1 mM 
each of cADPR, ADP-ribose, CDP-choline, 2′,3′-cAMP, Ap2A, ADP and ATP incubated with or without enzyme. 
All the nucleotidic compounds included in the mixture and their potential phosphohydrolytic products, at least 
the moieties that contain the nitrogen base, absorb at 260 nm, whereas only cADPR and its phosphohydrolytic 
product pRibAMP does so at 310 nm. Under the chromatographic conditions chosen, the no-enzyme control 
displayed seven well-resolved peaks of A260, each identified with one of the seven compounds included in the mix-
ture, while in the trace recorded at 310 nm only one significant peak appeared, that corresponded with cADPR. 
In the incubation run in the presence of the artificial cADPR phosphohydrolase, the only compound clearly 
consumed was cADPR, which was quantitatively converted to pRibAMP (in the trace recorded at 260 nm, this 
product nearly but not exactly coincided with Ap2A). In agreement with the expected specificity of cADPR phos-
phohydrolase, the other six compounds remained almost unaltered. Only minor amounts of 5′-CMP and 5′-AMP 
were detected as products. This could be accounted for by a 5% hydrolysis of CDP-choline, and by a summed-up 
1% hydrolysis of ADP-ribose and Ap2A. HPLC analyses of single nucleotides incubated with cADPR phosphohy-
drolase are shown in Supplementary Fig. S2 to confirm the nature of the products expected in less complex reac-
tion mixtures. These experiments demonstrate clearly the ability of cADPR phosphohydrolase to act specifically 
in the presence of other nucleotidic compounds.
Discussion
Emphasis must be put on the overwhelming effect of the F37A + L196F + V252A + C253G mutation set on the 
specificity of ADPRibase-Mn: compared to the wild-type enzyme, the substrate specificity or efficiency ratio 
cADPR/ADP-ribose increased >104-fold, from a ratio of 0.007 to as high as 80. For the rest of substrates, the 
Figure 4. Demonstration of the specificity of cADPR phosphohydrolase in complex nucleotidic mixtures. 
Mixtures of CDP-choline, cADPR, 2′,3′-cAMP, ADP-ribose, Ap2A, ADP and ATP, each at 0.1 mM 
concentration were incubated for 60 min at 37 °C in the absence or in the presence of 1 µg ml−1 of the specific 
cADPR phosphohydrolase under otherwise standard conditions. The chromatograms were run with buffers 
at pH 8.5 as described in Methods, and monitored at 260 nm and 310 nm. The retention times of all the 
substrates used and of most potential products expected (5′-CMP from CDP-choline; 5′-AMP from ADP-
ribose, Ap2A and ADP; 3′-AMP from 2′,3′-cAMP) were determined with samples of the standard compounds 
chromatographed individually. The pRibAMP produced by phosphohydrolysis of cADPR was characterised in 
previous work51.
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results indicated efficiency ratios of ≈20 to >1800 favourable to cADPR, representing increases of ≈400–
10000-fold with respect to the wild-type ADPRibase-Mn (Table 1). This picture portrays the conversion of a 
native enzyme defined as ADP-ribose/CDP-alcohol diphosphatase to an engineered enzyme that features as 
specific cADPR phosphohydrolase. This conversion is remarkable not only in terms of relative specificity or 
efficiency, when cADPR is compared to the other substrates, but also in a >20-fold increase of the absolute cata-
lytic efficiency for the phosphohydrolysis of cADPR, from 4 × 103 M−1 s−1 of wild-type ADPRibase-Mn to near 
105 M−1 s−1 of the engineered enzyme. One should recall that the median of the distribution of catalytic efficien-
cies in the enzymosphere lies at ≈105 M−1 s−1, and 60% of the enzymes with known catalytic efficiencies fall in 
the 104–106 M−1 s−1 range63. Therefore, the artificial cADPR phosphohydrolase seems well fit to act on cADPR in 
vitro and in vivo. The action in vitro was made manifest in experiments performed with mixtures of nucleotides, 
when the artificial enzyme was able to exhaust cADPR almost without affecting the other nucleotides (Fig. 4).
The change of specificity from wild-type ADPRibase-Mn to the specific cADPR phosphohydrolase is 
caused by mutations in amino acids apparently involved in substrate binding. In fact, considering those sub-
strates for which separate kcat and KM values were obtained (cADPR, ADP-ribose, CDP-choline, 2′,3′-cAMP; see 
Supplementary Fig. S1), it can be appreciated that the very high specificity for cADPR of the engineered enzyme 
depends on a relatively low KM value (≈140 µM for cADPR, and ≈12400 µM, 10600 µM and 8700 µM for the 
others) with little differences among kcat values (≈13 s−1 for cADPR, and ≈14 s−1, 37 s−1 and 12 s−1 for the others). 
None of the four mutated amino acids in the artificial specific cADPR phosphohydrolase (Phe37, Leu196, Val252, 
Cys253) appears to be directly involved in enzyme mechanism nor is part of the dinuclear centre. Actually, from 
earlier work55 it follows that mutations of amino acids involved in mechanism (Arg43, His111) or in the dinuclear 
metallic centre (Gln27, Asn110) do not provide any increase of specificity for cADPR.
The artificial specific cADPR phosphohydrolase constructed in this work makes a potentially useful tool 
for in vitro analytical applications, but overall it may be useful for in vivo functional studies of cADPR. This 
could be implemented by cell or organism transgenesis with cADPR phosphohydrolase cDNA under the control 
of an appropriate promoter, or by editing the ADPRibase-Mn gene (ADPRM) to introduce the F37A, L196F, 
V252A and C253G mutations (Phe37 and Leu196 in the ADPRM exon 2; Val252 and Cys253 in exon 4). The effects 
of cADPR removal are currently investigated by ablation of the CD38 gene64,65, but this does not always pro-
duce clean results. In some tissues of CD38 knockout mice, cADPR is far from being fully depleted5,14,65–70, most 
likely because other enzymes can also produce it46,69,71,72. The specific cADPR phosphohydrolase, if active in vivo, 
should deplete cADPR independently of its enzymatic source. This would probably occur with little effect on 
the other CD38 reactants (NAD+, ADP-ribose and NAADP) at variance of what happens with the CD38 knock-
out14,16,67,68,73. Anyhow, the use of cADPR phosphohydrolase, even if successfully removing cADPR, will not be 
without pitfalls. Particularly, one should consider that cADPR would be converted to pRibAMP, which is a prod-
uct of unknown fate and effects in animal cells. Concerning the minor activities of cADPR phosphohydrolase 
on substrates other than cADPR, it must be remarked that they would not probably represent novel intracel-
lular activities, since they are displayed by wild-type ADPRibase-Mn with much higher efficiencies (Table 1). 
Therefore, in transgenesis experiments those activities would bring about minor increases of background levels 
(unless the recombinant protein were heavily overexpressed), whereas in the case of ADPRM gene editing, they 
could be lower than in the non-edited cells. All in all, we believe that the in vivo expression of cADPR phospho-
hydrolase activity can provide excellent opportunities to study the effect of cADPR depletion as an alternative or 
as a complement to CD38 ablation.
Methods
Plasmids, enzymes and substrates. Plasmids pGEX-6P-3-hADPRM, harbouring the cloned human 
liver cDNA of the wild-type ADPRibase-Mn, and pGEX-6P-3-F37A + L196F-hADPRM, a double point mutant 
used as template for mutagenesis, were obtained as described55. Other plasmids were obtained by mutagenesis as 
described below. PfuTurbo DNA Polymerase from Agilent was used to generate mutated chains, and DpnI from 
New England Biolabs was used to degrade the methylated templates. The PreScissionTM protease was from GE 
Healthcare purchased through the VWR vendor in Spain. Phosphatase alkaline grade I used as auxiliary enzyme 
was a former Roche preparation purified from calf intestine purchased from Sigma-Aldrich. Substrates used 
to study the artificial cADPR phosphohydrolase and other ADPRibase-Mn mutants were obtained, including 
cADPR purified from the commercial preparation, from the sources described elsewhere51,58,59, except diadeno-
sine diphosphate (Ap2A, Sigma), nicotinic acid-adenine dinucleoside phosphate (NAADP, Sigma), and NADP+ 
(Roche, formerly Boehringer).
Mutagenesis. Mutations of coding sequences were implemented by the QuikChange protocol (Stratagene) 
using ad-hoc mutagenic primers and plasmid templates described in Table 2. The correctness of the full 
coding sequences obtained by mutagenesis was confirmed by double-strand sequencing in the Servicio 
de Genómica, Instituto de Investigaciones Biomédicas Alberto Sols, Consejo Superior de Investigaciones 
Científicas-Universidad Autónoma de Madrid, Madrid.
Protein expression and purification. Human recombinant ADPRibase-Mn and its mutants (all with 
the N-terminal extension GPLGSPNSRVD) were expressed, from pGEX-6P-3-hADPRM or from mutant plas-
mids, in E. coli BL21 cells, followed by affinity purification on GSH-Sepharose and specific proteolysis of the GST 
fusion protein with the PreScission protease to remove the GST tag55. Protein content was assayed in the final 
preparations74 and purity was estimated by image analysis of Coomassie Blue-stained SDS-PAGE gels with the 
GelAnalyzer 2010 software (http://www.gelanalyzer.com). In every case, a single major band of the expected size 
(i.e. ≈40.5 kDa) accounted for 64%–82% of protein in the gel lane. Considering that wild-type ADPRibase-Mn 
is 70% pure, the purity ratios of the mutants versus the wild-type ranged 0.91–1.17. Therefore, the minor purity 
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differences among the mutants and with respect to the wild-type do not affect to an important extent the estima-
tion of the kcat/KM changes caused by the mutations.
Enzyme assays. All the activities assayed correspond to phosphohydrolytic reactions of phosphoanhydride 
linkages except for the phosphodiesterase activity on 2′,3′-cAMP. The hydrolysis of cADPR, NADP+ and NAADP 
were assayed by HPLC measuring respectively the formation of pRibAMP, nicotinamide mononucleotide (NMN) 
or nicotinic acid mononucleotide (NAMN) as products (see below). The hydrolysis of the other substrates was 
assayed by colorimetric estimation of the amount of inorganic phosphate75 liberated from reaction products in 
the presence of an excess of alkaline phosphatase in the reaction mixture, except that for measuring the activities 
on ADP and ATP alkaline phosphatase was omitted.
The reaction mixtures contained, in a final volume of 0.1 ml, 50 mM Tris-HCl, pH 7.5 at 37 °C, 0.4 mM MnCl2, 
6.5 units ml−1 of alkaline phosphatase (only when needed, see above), 0.1 mg ml−1 bovine serum albumin, and 
variable amounts of the enzyme sample to be assayed. The reactions were initiated by addition of substrate at 
the required concentration after a 5-min preincubation of the reaction mixture at 37 °C. Enzyme incubations 
were terminated either by addition of a phosphate reagent75 or by injection in a HPLC column (see below). All 
the assays were run at 37 °C, under conditions of linearity with respect to incubation time and enzyme amount. 
Controls without enzyme and/or substrate were run in parallel to full reaction mixtures.
Estimation of specificity constants or catalytic efficiencies (kcat/KM). Two different methods were 
used to estimate the specificity constants or catalytic efficiencies on different substrates (see Supplementary 
Fig. S1). On the one hand, reaction kinetics was often profiled by measuring initial rates at serial substrate con-
centrations that approached at least a substantial fraction of half saturation. This allowed to estimate kcat and KM 
separately by nonlinear regression adjustment of the Michaelis-Menten equation to the data points, and thus to 
calculate kcat/KM. On the other hand, in a simpler approach, kcat/KM was estimated from reaction rates obtained 
well below the KM, when rate is (near) proportional to substrate concentration. Reaction rates were determined 
with different enzyme amounts at two substrate concentrations chosen to obtain a near-linear response versus 
substrate concentration. This does not provide separate estimations of kcat and KM, but under these conditions the 
Michaelis-Menten slope equals kcat/KM76. The two methods used to estimate kcat/KM gave similar results whenever 
both were applied to the same enzyme and substrate.
High performance liquid chromatography. Ion-pair reverse-phase HPLC was used to analyse the phos-
phohydrolysis of cADPR to pRibAMP, NADP+ to NMN, and NAADP to NAMN, with a HP-1100 chromatograph 
(Agilent) equipped with a manual injector, a 20-µl injection loop and a diode array detector. Chromatogram 
analyses were performed with the HP ChemStation software.
The assay of the phosphohydrolysis of cADPR was conducted by a modification of the method previously 
described51,55. The analyses were performed at 0.5 ml min−1 in a 200 mm × 2.1 mm octadecylsilica column (Hypersil 
ODS; Agilent) with a 20 mm × 2.1 mm guard column of the same material. For reaction mixtures aimed to assay 
the kinetics of cADPR phosphohydrolase, after sample injection, the chromatographic runs were developed with a 
10-min linear gradient of 5 mM–52.5 mM phosphate, using sodium phosphate buffers adjusted at pH 8.5, and con-
taining 20 mM tetrabutylammonium bromide and 10% (vol/vol) methanol. For reaction mixtures aimed to demon-
strate the phosphohydrolysis of cADPR in the presence of other nucleotidic compounds, the chromatographic runs 
were developed with a 2-min isocratic elution in 5 mM phosphate, followed by a 4-min linear gradient up to 43 mM 
phosphate, a 2-min linear gradient up to 100 mM phosphate, and finished with a 4-min isocratic wash, using sodium 
phosphate buffers like above. The elution profiles were monitored at 260 nm and 310 nm, the latter allowing the 
detection of compounds containing N1-ribosyl-adenine, like cADPR and its phosphohydrolytic product pRibAMP. 
Reaction rates were estimated from the cADPR-to-pRibAMP percent conversion.
For the assay of the phosphohydrolysis of NADP+ and NAADP, the analyses were run at 1 ml min−1 in a 
150 mm × 4 mm octadecylsilica column (Kromasil 100; Teknokroma, Sant Cugat del Vallés, Barcelona, Spain) 
with a 10 mm × 4 mm guard column of the same material. The chromatographic runs were developed with a 
5-min linear gradient of 5 mM–100 mM phosphate, followed by a 3-min isocratic wash, using sodium phosphate 
buffers (pH 7.0) with 5 mM tetrabutylammonium bromide and 20% (vol/vol) methanol. The elution profiles were 
monitored at 260 nm. Reaction rates were estimated either from the accumulation of NMN (retention time, tR, 
2.0 min) by hydrolysis of NADP+ (tR, 4.2 min) or from the accumulation of NAMN (tR, 3.1 min) by hydrolysis of 
NAADP (tR, 5.2 min). The amounts of NMN or NAMN formed were estimated by comparison to known quanti-
ties of the standard products.
Mutations Forward mutagenic primersa Template
1 F37A + L196F + C253G CCGGACGCGTCTGACAATGTGGGCCTGGCCTGGAACTACAG F37A + L196F-wtb
2 F37A + L196F + D250A + C253G CCCATTTACCCGGACGCGTCTGCAAATGTGGGCCTGGCCTGGAAC 1
3 F37A + L196F + V252A + C253G CCCGGACGCGTCTGACAATGCTGGCCTGGCCTGGAACTACAGAG 1
4 F37A + L196F + V252G + C253G CCCGGACGCGTCTGACAATGGTGGCCTGGCCTGGAACTACAGAG 1
5 F37A + L196F + V252A + C253G + T279A GGATCCTCAGAGTAGCCACCATCATGTGCGTGACCAGC 3
6 C253V CGGACGCCTCTGACAATGTGGTCCTGGCTTGGAACTACAG Wild-typeb
Table 2. Primers and plasmid templates used to construct ADPRibase-Mn mutants aReverse mutagenic 
primers were the exact reverse complement of those shown in the table bTemplate described elsewhere55.
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Data and materials availability. The DNA sequence coding for the quadruple mutant (F37A + L196F + 
V252A + C253G) of human ADPRibase-Mn with the N-terminal extension GPLGSPNSRVD, here character-
ised as artificial specific cADPR phosphohydrolase, has been deposited in GenBank with accession number 
MF447900. The rest of data generated or analysed during this study are included in this published article and 
its Supplementary Information files, or are available from the corresponding author. The plasmid pGEX-6P-
3-F37A + L196F + V252A + C253G-hADPRM, encoding the artificial cADPR phosphohydrolase, and the rest 
of materials generated during this study are available from the corresponding author upon reasonable request.
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